NexImmune Appoints Industry Veteran Chief Medical Officer to Executive Team
GAITHERSBURG, Md., Jan. 09, 2020 (originally published on GLOBE NEWSWIRE)
NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology platform, announced that industry veterans Han Myint, MD has been appointed as the Company’s Chief Medical Officer. Additionally, John Trainer, MBA has been appointed as the Chief Financial Officer.
Dr. Myint commented, “I am very excited to join NexImmune at such a time where I can leverage my professional experience to oversee the Company’s first two clinical trials for NEXI-001 and NEXI-002 in patients with relapsed forms of Acute Myeloid Leukemia (AML) and Multiple Myeloma, respectively. The Company has developed a novel technology that directs endogenous T cells against multiple tumor antigen targets. For patients suffering from a variety of cancers, I believe this approach has the potential to deliver potent anti-tumor activity while minimizing potential off-target toxicities, and I am looking forward to working with the team to make this a reality for these patients.”
Dr. Myint most recently served as the Vice President of Global Medical Affairs – Myeloid Diseases at Celgene. While in that role, he led the Global Franchise Team – Myeloid, and worked very closely with cross-functional teams representing commercial, market access, regulatory, translational and clinical functions to create a cohesive global disease strategy for all development-stage compounds in the Myeloid disease pipeline including AML, Myelodysplastic Syndrome (MDS), Myelofibrosis and Thalassemia. Prior to his six-year tenure at Celgene, Dr. Myint practiced academic hematology at multiple prestigious institutions, including Rush University in Chicago, and became a Fellow at the Royal College of Physicians and Royal College of Pathologists in London, England. He has the expertise and clinical experience in hematological malignancies and stem cell transplantation. Additionally, Dr. Myint built a FACT-accredited and Center of Excellence-Designated Transplant Program at the University of Colorado, Denver, while becoming a fellow of the American College of Physicians.
Scott Carmer, President and CEO of NexImmune, commented on the additions to the Company’s Executive Leadership Team, “I am thrilled to have both Han and John join our team. Individually, each is a highly respected and accomplished industry leader. Together, their combined experience, expertise and leadership will be a strong complement to those of our existing executive team. As we initiate our first clinical trials in 1Q2020, NexImmune is now poised to exploit the full potential of our unique technology platform for the benefit of patients in need.”
NexImmune is a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on the proprietary Artificial Immune Modulation (AIM) nanotechnology platform. The AIM platform enables the ability to expand multi-antigen specific T cells with enhanced anti-tumor properties without the need for genetic manipulation. NexImmune is leveraging the AIM technology platform to develop a pipeline of products to treat cancer and auto-immune diseases.
Latest posts by Chris Frew (see all)
- Moustapha El-Amine, Ph.D. Joins Insmed Incorporated as Executive Director of Global Search and Evaluation (S&E) - October 29, 2020
- JHU Spinout Thrive Earlier Detection Lands up to $2.15 Billion in Acquisition by Exact Sciences - October 27, 2020
- Vigene Biosciences Appoints Audrey Chang, Ph.D. as VP of QC and Analytical Services - October 26, 2020